학술논문
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Document Type
Original Paper
Author
Lyke, Kirsten E.; Atmar, Robert L.; Dominguez Islas, Clara; Posavad, Christine M.; Deming, Meagan E.; Branche, Angela R.; Johnston, Christine; El Sahly, Hana M.; Edupuganti, Srilatha; Mulligan, Mark J.; Jackson, Lisa A.; Rupp, Richard E.; Rostad, Christina A.; Coler, Rhea N.; Bäcker, Martín; Kottkamp, Angelica C.; Babu, Tara M.; Dobrzynski, David; Martin, Judith M.; Brady, Rebecca C.; Frenck, Jr., Robert W.; Rajakumar, Kumaravel; Kotloff, Karen; Rouphael, Nadine; Szydlo, Daniel; PaulChoudhury, Rahul; Archer, Janet I.; Crandon, Sonja; Ingersoll, Brian; Eaton, Amanda; Brown, Elizabeth R.; McElrath, M. Juliana; Neuzil, Kathleen M.; Stephens, David S.; Post, Diane J.; Lin, Bob C.; Serebryannyy, Leonid; Beigel, John H.; Montefiori, David C.; Roberts, Paul C.
Source
npj Vaccines. 8(1)
Subject
Language
English
ISSN
2059-0105
Abstract
Abstract: As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.